Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD - Vienna 2024

Clinical and translational studies of asthma and chronic obstructive pulmonary disease: novel treatment targets

Chair(s): Lena Uller, Ian M. Adcock

Session type: Oral presentation

Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD

Dave Singh

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD

Dave Singh

Replay

Poster

Abstract

Slides

Resting-state CNS networks in refractory/unexplained chronic cough

James Wingfield Digby

Replay

Poster

Abstract

Slides

Pan-antiviral effects of RIG-I agonist (RIG-101) against respiratory syncytial virus and human rhinovirus in nasal epithelium in vitro and mice in vivo

Kazuhiro Ito

Replay

Poster

Abstract

Slides

Targeting SOCE attenuates IL-17-driven airway inflammation in cigarette smoking-induced COPD mice

Zijian Zeng

Replay

Poster

Abstract

Slides

TSLP blocking modifies cross-talk between airway epithelium and macrophages reducing macrophage activation

Elisabetta Pace

Replay

Poster

Abstract

Slides

Histological evaluation of GR and HDAC expression in endobronchial biopsies of COPD patients with known responsiveness to ICS: Insights from the HISTORIC study

Eleni Papakonstantinou

Replay

Abstract

Slides

Reversing oxidative stress-induced senescence in small airway epithelial cells using the mTOR inhibitor AZD8055

Faye Shrosbery

Replay

Poster

Abstract

Slides

Effect of azithromycin on epithelial antiviral immunity in patients with asthma (AZIMUNE-study)

Th?r?se Lapperre

Replay

Abstract

Slides

A phase 1 study of SHR-1905, a long-acting anti-TSLP monoclonal antibody, in healthy subjects and patients with asthma

Yang Zou

Replay

Poster

Abstract

Slides

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}